There are a number of SPHK1 and S1P inhibitors in clinical development as anti-cancer agents that confer increased sensitivity to cytotoxic drugs, targeted agents or radiotherapy and/or have single agent activity in preclinical cancer models [30, 31, 38, 44–49] (Table 2). Here, SPHK1 is linked to cancer.